HilleVax, Inc.

Equities

HLVX

US43157M1027

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 17/06/2024 BST 5-day change 1st Jan Change
15.29 USD +1.33% Intraday chart for HilleVax, Inc. +9.21% -4.74%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Recursion Names HilleVax CEO Robert Hershberg as New Board Chair MT
Hillevax Insider Sold Shares Worth $266,291, According to a Recent SEC Filing MT
HilleVax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Hillevax Insider Sold Shares Worth $264,467, According to a Recent SEC Filing MT
Stifel Adjusts HilleVax Price Target to $34 From $30, Maintains Buy Rating MT
HilleVax Insider Sold Shares Worth $985,536,428, According to a Recent SEC Filing MT
HilleVax Proposes $500 Million Offering of Equity, Debt Securities in Shelf Registration MT
HilleVax Q4 Net Loss Widens; Shares Extend Decline After Hours MT
HilleVax, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
HilleVax, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
HilleVax Names New Chief Operating Officer MT
HilleVax Taps Sean McLoughlin as Chief Operating Officer DJ
HilleVax, Inc. Announces Executive Changes CI
Kanghua Biological Products Licenses Norovirus Vaccine to HilleVax MT
Certain Options of HilleVax, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2023. CI
Certain Restricted Stock Units of HilleVax, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2023. CI
Certain Common Stock of HilleVax, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2023. CI
HilleVax, Inc.(NasdaqGS:HLVX) dropped from NASDAQ Biotechnology Index CI
HC Wainwright Initiates HilleVax With Buy Rating MT
Hillevax Insider Sold Shares Worth $287,000, According to a Recent SEC Filing MT
Hillevax Insider Sold Shares Worth $140,000, According to a Recent SEC Filing MT
HilleVax Q3 Net Loss Widens MT
HilleVax, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
HilleVax Prices $100 Million Common Stock Offering MT
HilleVax, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Chart HilleVax, Inc.
More charts
HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. The Company's program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral AGE worldwide and is characterized by symptoms, including diarrhea, vomiting, abdominal pain, nausea, and, sometimes, fever that may lead to clinically significant dehydration. The Company's HIL-214 is a bivalent (containing two proteins) vaccine candidate consisting of VLPs representing two common genotypes of norovirus and is co-formulated with an aluminum hydroxide (alum) adjuvant, which is commonly used in adult and pediatric vaccines to enhance immunogenicity. HIL-216 includes six common norovirus genotypes, GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
15.29 USD
Average target price
29.6 USD
Spread / Average Target
+93.59%
Consensus
  1. Stock Market
  2. Equities
  3. HLVX Stock
  4. News HilleVax, Inc.
  5. Recursion Names HilleVax CEO Robert Hershberg as New Board Chair
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW